Companies / NextCure, Inc.
NextCure, Inc.
Nasdaq: NXTCCIK 1661059BELTSVILLE, MD
Financials · FY2020
Ownership
4.6M shares outstanding · as of Jul 31, 2026
Ownership
| 10%+ / strategic | 3.85% | 176,057 |
| Institutions | 38.62% | 1,767,875 |
| Public float | 57.53% | 2,633,427 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 8
View all →| Insider | % of shares | Shares |
|---|---|---|
Cobourn Steven P.Chief Financial Officer | — | — |
Guha UdayanChief Medical Officer | — | — |
Jones Elaine VDirector | — | — |
Kabakoff David SDirector | — | — |
Kundu SouravSr VP, Dev. & Mfg. | — | — |
Mayer TimothyChief Operating Officer | — | — |
Richman MichaelCEOPresident & CEO · Director | — | — |
Shaw Kevin G.Sr VP, General Counsel | — | — |
Institutional holders 25
View all →| Holder | Value | % of shares |
|---|---|---|
| $3.51M | 5.40% | |
| $3.38M | 5.21% | |
| $3.36M | 5.18% | |
| $3.16M | 4.86% | |
| $2.50M | 3.85% | |
| $2.34M | 3.60% | |
| $2.24M | 3.44% | |
| $1.67M | 2.56% | |
| $1.30M | 2.01% | |
| $987.9K | 1.52% |
Activity
InsidersInstitutions
What insiders are doing in this stock (Form 4).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Jun 18, 2026 | Jones Elaine V Director | Grant | Stock Option (Right to Buy) | — | +2K | 2,340 0.05% of shares | low |
| Jun 18, 2026 | Kabakoff David S Director | Grant | Stock Option (Right to Buy) | — | +4K | 3,510 0.08% of shares | low |
| Jan 30, 2026 | Mayer Timothy Executive | Grant | Employee Stock Option (Right to Buy) | — | +15K | 14,670 0.32% of shares | low |
| Jan 30, 2026 | Cobourn Steven P. Executive | Grant | Employee Stock Option (Right to Buy) | — | +15K | 14,670 0.32% of shares | low |
| Jan 30, 2026 | Shaw Kevin G. Executive | Grant | Employee Stock Option (Right to Buy) | — | +8K | 8,270 0.18% of shares | low |
| Jan 30, 2026 | Richman Michael CEO | Grant | Employee Stock Option (Right to Buy) | — | +38K | 38,190 0.83% of shares | low |
| Jan 30, 2026 | Kundu Sourav Executive | Grant | Employee Stock Option (Right to Buy) | — | +8K | 8,270 0.18% of shares | low |
| Jan 30, 2026 | Guha Udayan Executive | Grant | Employee Stock Option (Right to Buy) | — | +15K | 14,670 0.32% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Affinity Asset Advisors, LLC | Passive13G/A | — |
| Pfizer Inc | Passive13G/A | — |
| Squadron Master Fund LP | Passive13G/A | — |
| SilverArc Capital Management, LLC | Passive13G | — |
| Ikarian Capital, LLC | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| NXTC | Common Stock | 65343E207 |